Upadacitinib and Baricitinib belong to which class?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Prepare for the Dermatology Week 1 Exam with comprehensive study materials. Practice with detailed questions, flashcards, and expert explanations. Boost your knowledge and confidence for the exam!

Multiple Choice

Upadacitinib and Baricitinib belong to which class?

Explanation:
JAK inhibitors. These drugs block the JAK-STAT signaling pathway, which transmits signals from multiple inflammatory cytokines involved in skin diseases. Upadacitinib and Baricitinib are small-molecule medications taken orally that inhibit JAK enzymes—Upadacitinib mainly targets JAK1, while Baricitinib inhibits JAK1 and JAK2—reducing the activation of STATs and the expression of inflammatory genes. This mechanism is different from anti-TNF monoclonal antibodies, calcineurin inhibitors, or PDE-5 inhibitors, which act on other targets.

JAK inhibitors. These drugs block the JAK-STAT signaling pathway, which transmits signals from multiple inflammatory cytokines involved in skin diseases. Upadacitinib and Baricitinib are small-molecule medications taken orally that inhibit JAK enzymes—Upadacitinib mainly targets JAK1, while Baricitinib inhibits JAK1 and JAK2—reducing the activation of STATs and the expression of inflammatory genes. This mechanism is different from anti-TNF monoclonal antibodies, calcineurin inhibitors, or PDE-5 inhibitors, which act on other targets.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy